tetano
Editor, Senior Moderator
J Med Virol
. 2023 Mar 22.
doi: 10.1002/jmv.28695. Online ahead of print.
Humoral responses after primary and booster SARS-CoV-2 inactivated vaccination in patients with chronic hepatitis B virus infection: a longitudinal observational study
Zhiwei Chen[SUP] 1 [/SUP], Tianquan Huang[SUP] 1 [/SUP], Taiyu He[SUP] 1 [/SUP], Guanhua Zha[SUP] 1 [/SUP], Qian Zhu[SUP] 1 [/SUP], Gaoli Zhang[SUP] 1 [/SUP], Dejuan Xiang[SUP] 1 [/SUP], Min Chen[SUP] 1 [/SUP], Hu Li[SUP] 1 [/SUP], Ning Ling[SUP] 1 [/SUP], Yinghua Lan[SUP] 1 [/SUP], Shi Xiaofeng[SUP] 1 [/SUP], Dazhi Zhang[SUP] 1 [/SUP], Pan Xu[SUP] 1 [/SUP], Qingbo Pan[SUP] 1 [/SUP], Rui Song[SUP] 1 [/SUP], Junxiong Cao[SUP] 1 [/SUP], Yingzhi Zhang[SUP] 1 [/SUP], Hongyan Xiang[SUP] 1 [/SUP], Yali Feng[SUP] 1 [/SUP], Ziqiao Yang[SUP] 1 [/SUP], Biqiong Zhang[SUP] 1 [/SUP], Wei Shen[SUP] 1 [/SUP], Dachuan Cai[SUP] 1 [/SUP], Mingli Peng[SUP] 1 [/SUP], Peng Hu[SUP] 1 [/SUP], Hong Ren[SUP] 1 [/SUP]
Affiliations
Abstract
Given the pandemic of severe acute respiratory syndrome coronavirus 2 Omicron variants, booster vaccination (BV) using inactivated virus vaccines (the third dose) has been implemented in China. However, the immune responses after BV, especially those against Omicron, in patients with chronic hepatitis B virus (HBV) infection (CHB) are unclear. In this prospective longitudinal study, 114 patients with CHB and 68 healthy controls (HCs) were recruited after receiving inactivated vaccination. The anti-receptor-binding domain (RBD) immunoglobulin G (IgG), neutralizing antibodies (NAbs), neutralization against Omicron (BA2.12.1, BA.4/5), and specific B/T cells were evaluated. In patients, anti-RBD IgG was elevated significantly after BV; the titers were as high as those in HCs. Similar results were obtained for the NAbs. However, compared with that against wild type (WT), the neutralization against Omicron was compromised after BV. The frequency of RBD[SUP]+[/SUP] atypical memory B cells increased, but spike-specific cluster of differentiation 4[SUP]+[/SUP] /8[SUP]+[/SUP] T cells remained unchanged after BV. Moreover, no serious adverse events or HBV reactivation were observed after BV. These results suggest that BV significantly enhanced antibody responses against WT; however, it resulted in compromised antibody responses against Omicron in patients with CHB. Hence, new all-in-one vaccines and optimal vaccination strategies should be studied promptly. This article is protected by copyright. All rights reserved.
Keywords: COVID-19; Omicron variants; SARS-CoV-2; chronic hepatitis B virus infection; immunogenicity; inactivated vaccines.
. 2023 Mar 22.
doi: 10.1002/jmv.28695. Online ahead of print.
Humoral responses after primary and booster SARS-CoV-2 inactivated vaccination in patients with chronic hepatitis B virus infection: a longitudinal observational study
Zhiwei Chen[SUP] 1 [/SUP], Tianquan Huang[SUP] 1 [/SUP], Taiyu He[SUP] 1 [/SUP], Guanhua Zha[SUP] 1 [/SUP], Qian Zhu[SUP] 1 [/SUP], Gaoli Zhang[SUP] 1 [/SUP], Dejuan Xiang[SUP] 1 [/SUP], Min Chen[SUP] 1 [/SUP], Hu Li[SUP] 1 [/SUP], Ning Ling[SUP] 1 [/SUP], Yinghua Lan[SUP] 1 [/SUP], Shi Xiaofeng[SUP] 1 [/SUP], Dazhi Zhang[SUP] 1 [/SUP], Pan Xu[SUP] 1 [/SUP], Qingbo Pan[SUP] 1 [/SUP], Rui Song[SUP] 1 [/SUP], Junxiong Cao[SUP] 1 [/SUP], Yingzhi Zhang[SUP] 1 [/SUP], Hongyan Xiang[SUP] 1 [/SUP], Yali Feng[SUP] 1 [/SUP], Ziqiao Yang[SUP] 1 [/SUP], Biqiong Zhang[SUP] 1 [/SUP], Wei Shen[SUP] 1 [/SUP], Dachuan Cai[SUP] 1 [/SUP], Mingli Peng[SUP] 1 [/SUP], Peng Hu[SUP] 1 [/SUP], Hong Ren[SUP] 1 [/SUP]
Affiliations
- PMID: 36946505
- DOI: 10.1002/jmv.28695
Abstract
Given the pandemic of severe acute respiratory syndrome coronavirus 2 Omicron variants, booster vaccination (BV) using inactivated virus vaccines (the third dose) has been implemented in China. However, the immune responses after BV, especially those against Omicron, in patients with chronic hepatitis B virus (HBV) infection (CHB) are unclear. In this prospective longitudinal study, 114 patients with CHB and 68 healthy controls (HCs) were recruited after receiving inactivated vaccination. The anti-receptor-binding domain (RBD) immunoglobulin G (IgG), neutralizing antibodies (NAbs), neutralization against Omicron (BA2.12.1, BA.4/5), and specific B/T cells were evaluated. In patients, anti-RBD IgG was elevated significantly after BV; the titers were as high as those in HCs. Similar results were obtained for the NAbs. However, compared with that against wild type (WT), the neutralization against Omicron was compromised after BV. The frequency of RBD[SUP]+[/SUP] atypical memory B cells increased, but spike-specific cluster of differentiation 4[SUP]+[/SUP] /8[SUP]+[/SUP] T cells remained unchanged after BV. Moreover, no serious adverse events or HBV reactivation were observed after BV. These results suggest that BV significantly enhanced antibody responses against WT; however, it resulted in compromised antibody responses against Omicron in patients with CHB. Hence, new all-in-one vaccines and optimal vaccination strategies should be studied promptly. This article is protected by copyright. All rights reserved.
Keywords: COVID-19; Omicron variants; SARS-CoV-2; chronic hepatitis B virus infection; immunogenicity; inactivated vaccines.